Well differentiated thyroid carcinomas: p53 mutation status and microvessel density

被引:0
作者
Goldenberg, JD
Portugal, LG
Wenig, BL
Ferrer, K
Wu, JC
Sabnani, J
机构
[1] Univ Illinois, Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60612 USA
[2] Univ Illinois, Dept Pathol, Chicago, IL USA
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 1998年 / 20卷 / 02期
关键词
thyroid; carcinoma; p53; CD34; microvessel density;
D O I
10.1002/(SICI)1097-0347(199803)20:2<152::AID-HED9>3.3.CO;2-X
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Risk-stratification schemes exist for well-differentiated thyroid carcinoma and include prognostic factors such as age, sex, extent of tumor, size Of tumor, and presence of metastasis. Controversy continues, however, over the aggressiveness of initial surgical intervention because of anecdotal experiences of poor clinical outcomes in low-risk patients. Our objective is to determine the prognostic significance of two biologic tumor markers, the p53 gene mutation and CD34 microvessel density (MVD) count, in well-differentiated tumors of thyroid gland. Methods. We selected 38 patients with well-differentiated thyroid carcinomas from the University of Illinois Tumor Registry. Patients had an ave-rage clinical follow-up of 10 years. Paraffin embedded tumor specimens were available for all patients. Immunohistochemistry was performed to identify mutations of the p53 gene (Ab 1801) and to determine the MVD count (CD34). Results. There were significant increases in MVD counts within thyroid tumor tissue, when compared with surrounding, normal thyroid tissue. There was no significant correlation noted, however, between increased MVD and histology or recurrence rates, There was a trend toward higher MVD counts in tumor specimens of patients initially seen with metastatic lymphadenopathy. The incidence of p53 mutation expression was 28%, and there was no correlation between p53 status and histology, sex, recurrence rate, or survival, Conclusions. This study supports the concept of tumor neovascularization but fails to correlate MVD with clinical behavior or pathologic features in well-differentiated thyroid carcinoma, Furthermore, we found that the p53 mutation status was not an independent prognosticator of tumor behavior in these lesions. (C) 1998 John Wiley & Sons, Inc.
引用
收藏
页码:152 / 158
页数:7
相关论文
共 31 条
  • [1] MICROVESSEL QUANTITATION AND PROGNOSIS IN INVASIVE BREAST-CARCINOMA
    BOSARI, S
    LEE, AKC
    DELELLIS, RA
    WILEY, BD
    HEATLEY, GJ
    SILVERMAN, ML
    [J]. HUMAN PATHOLOGY, 1992, 23 (07) : 755 - 761
  • [2] CADY B, 1988, SURGERY, V104, P947
  • [3] STEPWISE PARTICIPATION OF P53 GENE MUTATION DURING DEDIFFERENTIATION OF HUMAN THYROID CARCINOMAS
    DOBASHI, Y
    SUGIMURA, H
    SAKAMOTO, A
    MERNYEI, M
    MORI, M
    OYAMA, T
    MACHINAMI, R
    [J]. DIAGNOSTIC MOLECULAR PATHOLOGY, 1994, 3 (01) : 9 - 14
  • [4] GENE P53 MUTATIONS ARE RESTRICTED TO POORLY DIFFERENTIATED AND UNDIFFERENTIATED CARCINOMAS OF THE THYROID-GLAND
    DONGHI, R
    LONGONI, A
    PILOTTI, S
    MICHIELI, P
    DELLAPORTA, G
    PIEROTTI, MA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) : 1753 - 1760
  • [5] ANGIOGENESIS AS A PROGNOSTIC MARKER IN EARLY HEAD AND NECK-CANCER
    DRAY, TG
    HARDIN, NJ
    SOFFERMAN, RA
    [J]. ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1995, 104 (09) : 724 - 729
  • [6] HIGH PREVALENCE OF MUTATIONS OF THE P53 GENE IN POORLY DIFFERENTIATED HUMAN THYROID CARCINOMAS
    FAGIN, JA
    MATSUO, K
    KARMAKAR, A
    CHEN, DL
    TANG, SH
    KOEFFLER, HP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) : 179 - 184
  • [7] FINA L, 1990, BLOOD, V75, P2417
  • [8] ACTIVATING MUTATIONS FOR TRANSFORMATION BY P53 PRODUCE A GENE-PRODUCT THAT FORMS AN HSC70-P53 COMPLEX WITH AN ALTERED HALF-LIFE
    FINLAY, CA
    HINDS, PW
    TAN, TH
    ELIYAHU, D
    OREN, M
    LEVINE, AJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (02) : 531 - 539
  • [9] INTRATUMORAL MICROVESSEL DENSITY AND P53 PROTEIN - CORRELATION WITH METASTASIS IN HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
    GASPARINI, G
    WEIDNER, N
    MALUTA, S
    POZZA, F
    BORACCHI, P
    MEZZETTI, M
    TESTOLIN, A
    BEVILACQUA, P
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (05) : 739 - 744
  • [10] TUMOR DORMANCY IN-VIVO BY PREVENTION OF NEOVASCULARIZATION
    GIMBRONE, MA
    COTRAN, RS
    FOLKMAN, J
    LEAPMAN, SB
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1972, 136 (02) : 261 - &